Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026February 5, 2026 Interim analysis of a pivotal insomnia clinical trial that could pave the way for Australia’s first […]
News in brief: Puro completes first hash export; GrowerIQ renews GMP compliance; MedReleaf inks Leafio deal; Vitura forms advisory group; Althea to become Peak Processing by Adam Sheldon December 2, 2025December 4, 2025
News in brief: Epsilon receives EU, UK GMP certificates; AGH raises $2.6m via placement; Zelira secures loan notes; Bioxyne’s $5m German order by Steve Jones September 17, 2025September 17, 2025
Althea CEO blames Covid and TGA for demise of pharma division by Steve Jones May 20, 2025May 20, 2025
Althea blames medical sales decline on TGA ‘falling asleep at the wheel’ amid ‘crazy’ antics of competitors by Steve Jones March 21, 2025March 26, 2025
Althea claims profitability ‘is close’ despite pharmaceutical nosedive by Steve Jones March 3, 2025March 4, 2025
Changes on the horizon but exit of pharmaceutical market ‘not currently on the table’, says Althea CEO by Steve Jones February 20, 2025February 20, 2025
Althea resumes trading on ASX as board narrowly avoids a second shareholder revolt by Steve Jones February 3, 2025February 3, 2025
Althea reports cash flow positive quarter but shaves top end of revenue guidance by Steve Jones October 31, 2024February 25, 2025
Impairment charge sees Althea losses sink to $32m despite revenue growth by Steve Jones August 30, 2024September 2, 2024
